Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
February 07, 2025 18:35 ET
|
Oculis Holding AG
ZUG, Switzerland, Feb. 08, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.
...
Matthews International Issues Statement Following ISS Report
February 07, 2025 18:30 ET
|
Matthews International Corporation
PITTSBURGH, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matthews International Corporation (Nasdaq GSM: MATW) (“Matthews” or the “Company”) issued the following statement regarding a February 6, 2025 report...
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
February 07, 2025 16:58 ET
|
Pliant Therapeutics, Inc.
Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO,...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025 16:30 ET
|
Neuronetics
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025 16:30 ET
|
Tempest Therapeutics
BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025 16:30 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...
Callan JMB Announces Partial Exercise of Underwriters’ Over-Allotment Option in Connection with its Initial Public Offering
February 07, 2025 16:15 ET
|
Callan JMB Inc.
SPRING BRANCH, Texas, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency...
Brera Holdings Announces Anticipated Receipt of Nasdaq Additional Deficiency Notice
February 07, 2025 16:15 ET
|
Brera Holdings PLC
Dublin, Ireland, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Brera Holdings PLC (“Brera Holdings” or “the Company”) (Nasdaq: BREA), an Ireland-based, Nasdaq-listed, international holding company focused on...
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...